Angela Bellini et al.
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Journal of Clinical Oncology 2021, vol. 39, issue 30
doi: 10.1200/jco.21.00086